NAV

Meticrane

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Meticrane
DrugBank Accession Number
DB13284
Background

Meticrane is a diuretic medication. It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure 1.

Type
Small Molecule
Groups
Approved
Structure
3D
Similar Structures
Weight
Average: 275.34
Monoisotopic: 275.028600251
Chemical Formula
C10H13NO4S2
Synonyms
  • Meticrane
External IDs
  • SD 17102
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbacavirMeticrane may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Meticrane.
AceclofenacMeticrane may increase the excretion rate of Aceclofenac which could result in a lower serum level and potentially a reduction in efficacy.
AcemetacinThe therapeutic efficacy of Meticrane can be decreased when used in combination with Acemetacin.
AcetaminophenMeticrane may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
Food Interactions
Not Available

Categories

ATC Codes
G01AE10 — Combinations of sulfonamidesC03BA09 — Meticrane
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as thiochromanes. These are organic heterocyclic compounds containing a thiochromane moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiochromanes
Sub Class
Not Available
Direct Parent
Thiochromanes
Alternative Parents
1-benzothiopyrans / Thiopyrans / Organosulfonamides / Benzenoids / Sulfones / Aminosulfonyl compounds / Organic oxides / Organic nitrogen compounds / Hydrocarbon derivatives
Substituents
1-benzothiopyran / Aminosulfonyl compound / Aromatic heteropolycyclic compound / Benzenoid / Benzothiopyran / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic sulfonic acid or derivatives
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
I7EKN1924Q
CAS number
1084-65-7
InChI Key
FNQQBFNIYODEMB-UHFFFAOYSA-N
InChI
InChI=1S/C10H13NO4S2/c1-7-5-8-3-2-4-16(12,13)10(8)6-9(7)17(11,14)15/h5-6H,2-4H2,1H3,(H2,11,14,15)
IUPAC Name
6-methyl-1,1-dioxo-3,4-dihydro-2H-1λ⁶-benzothiopyran-7-sulfonamide
SMILES
CC1=CC2=C(C=C1S(N)(=O)=O)S(=O)(=O)CCC2

References

General References
  1. Kegg Drug - Meticrane [Link]
ChemSpider
4021
ChEBI
31839
ChEMBL
CHEMBL1318341
ZINC
ZINC000000001718
Wikipedia
Meticrane

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.679 mg/mLALOGPS
logP0.2ALOGPS
logP0.57Chemaxon
logS-2.6ALOGPS
pKa (Strongest Acidic)9.96Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area94.3 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity65.09 m3·mol-1Chemaxon
Polarizability26.34 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0090000000-16c96f6e44722085207b
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0090000000-b9e7c083a54620d1a031
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-056r-0090000000-f6fe9d8330bc2b3cd04c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-3090000000-91e8e8ada8f307f42ce0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-1920000000-990165f590aaa13e698d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9510000000-5aa7c9c2fc10c97d8933
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-165.1429528
predicted
DarkChem Lite v0.1.0
[M-H]-150.76735
predicted
DeepCCS 1.0 (2019)
[M+H]+166.6676528
predicted
DarkChem Lite v0.1.0
[M+H]+153.16292
predicted
DeepCCS 1.0 (2019)
[M+Na]+159.19273
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:39 / Updated at February 21, 2021 18:54